Page 105 - Read Online

Page 16 of 20 Zhang et al. Cancer Drug Resist 2024;7:34 https://dx.doi.org/10.20517/cdr.2024.59

pathway in cisplatin-resistant nasopharyngeal carcinoma cells. Gene 2019;710:103-13. DOI PubMed
71. Gu J, Han T, Sun L, Yan AH, Jiang XJ. miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53
pathway. Cell Cycle 2020;19:1012-21. DOI PubMed PMC
72. Sheng S, Su W, Mao D, et al. MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma. PLoS One
2022;17:e0267017. DOI PubMed PMC
73. Wu R, Zhong Q, Liu H, Liu S. MicroRNA-577/EIF5A2 axis suppressed the proliferation of DDP-resistant nasopharyngeal carcinoma
cells by blocking TGF-β signaling pathway. Chem Biol Drug Des 2023;102:815-27. DOI PubMed
74. Chen L, Zhu Q, Lu L, Liu Y. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral
squamous cell carcinoma cells via targeting TGF-β1. Bioengineered 2020;11:91-102. DOI PubMed PMC
75. Luo HQ, Wang Y, Ren J, et al. MiRNA-296-5p promotes the sensitivity of nasopharyngeal carcinoma cells to cisplatin via targeted
inhibition of STAT3/KLF4 signaling axis. Sci Rep 2024;14:6681. DOI PubMed PMC
76. Chen S, Yang M, Wang C, et al. Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral
squamous cell carcinoma. Cancer Lett 2021;503:43-53. DOI PubMed
77. Yang S, Yuan ZJ, Zhu YH, Chen X, Wang W. lncRNA PVT1 promotes cetuximab resistance of head and neck squamous cell
carcinoma cells by inhibiting miR-124-3p. Head Neck 2021;43:2712-23. DOI PubMed
78. Yuan F, Lou Z, Zhou Z, Yan X. [Retracted] Long non-coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin
resistance via the miR 454/USP47 axis. Int J Mol Med 2024;53:31. DOI PubMed PMC
79. Yan P, Su Z, Zhang Z, Gao T. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by
sponging miR 9 5p and regulating SPAG9 expression. Int J Oncol 2019;55:988-1002. DOI PubMed PMC
80. Hong X, Liu N, Liang Y, et al. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and
docetaxel chemoresistance through upregulating FOXQ1. Mol Cancer 2020;19:33. DOI PubMed PMC
81. Yuan Z, Xiu C, Liu D, et al. Long noncoding RNA LINC-PINT regulates laryngeal carcinoma cell stemness and chemoresistance
through miR-425-5p/PTCH1/SHH axis. J Cell Physiol 2019;234:23111-22. DOI PubMed
82. Liu J, Zhu M, Tang Q. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-181a retards nasopharyngeal
carcinoma development by mediating KDM5C. J Cancer Res Clin Oncol 2021;147:2867-77. DOI PubMed
83. Song A, Wu Y, Chu W, et al. Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell
carcinoma. Int J Biol Sci 2021;17:430-47. DOI PubMed PMC
84. Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet 2022;38:613-26. DOI
PubMed
85. Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev
2022;182:114113. DOI PubMed
86. Jiménez-Morales JM, Hernández-Cuenca YE, Reyes-Abrahantes A, et al. MicroRNA delivery systems in glioma therapy and
perspectives: a systematic review. J Control Release 2022;349:712-30. DOI PubMed
87. Han J, LaVigne CA, Jones BT, Zhang H, Gillett F, Mendell JT. A ubiquitin ligase mediates target-directed microRNA decay
independently of tailing and trimming. Science 2020;370:eabc9546. DOI PubMed PMC
88. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell
Biol 2021;22:96-118. DOI PubMed PMC
89. Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol
2022;23:389-406. DOI PubMed
90. Zhang Y, Luo M, Cui X, O’Connell D, Yang Y. Long noncoding RNA NEAT1 promotes ferroptosis by modulating the miR-362-3p/
MIOX axis as a ceRNA. Cell Death Differ 2022;29:1850-63. DOI PubMed PMC
91. Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat
2022;63:100851. DOI PubMed
92. Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From
prediction to druggability. Drug Resist Updat 2022;65:100866. DOI PubMed
93. Yu Z, Tang H, Chen S, et al. Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-
induced autophagy. Drug Resist Updat 2023;67:100915. DOI PubMed
94. Gao Y, Shang S, Guo S, et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer
associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Res 2021;49:D1251-8. DOI PubMed PMC
95. Carlevaro-Fita J, Lanzós A, Feuerbach L, et al; PCAWG Drivers and Functional Interpretation Group; PCAWG Consortium. Cancer
LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol
2020;3:56. DOI PubMed PMC
96. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019;88:102925. DOI PubMed
97. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78. DOI
PubMed PMC
98. Perego P. Tackling cisplatin resistance in ovarian cancer: what can we do? Cancer Drug Resist 2021;4:755-7. DOI PubMed PMC
99. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 2016;106:27-36. DOI PubMed
100. Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014;5:e1257.
DOI PubMed PMC